Form 4 · Statement of Changes in Beneficial Ownership · Filed 2025-10-01
Garg Pushkal Files Alnylam Pharmaceuticals (ALNY) Form 4 - October 01, 2025
Garg Pushkal traded 11.9K ALNY shares worth $2.7M in this Form 4 filing, reported to the SEC on 2025-10-01.
- Insider
- Garg Pushkal
- Issuer
- Alnylam Pharmaceuticals Inc. ALNY · NASDAQ
- Filed
- Period
- 2025-10-01
- Accession
- 0001735276-25-000113
- Source
- Official filing on sec.gov ↗
Transactions (19)
| Insider | Date | Type | Shares | Price | Value | Own |
|---|---|---|---|---|---|---|
| Garg Pushkal | 2025-10-03 | Sell | 215 | $454.37 | $97.7K | Direct |
| Garg Pushkal | 2025-10-03 | Sell | 417 | $453.51 | $189.1K | Direct |
| Garg Pushkal | 2025-10-03 | Sell | 682 | $449.99 | $306.9K | Direct |
| Garg Pushkal | 2025-10-03 | Sell | 810 | $450.63 | $365.0K | Direct |
| Garg Pushkal | 2025-10-03 | Sell | 898 | $451.76 | $405.7K | Direct |
| Garg Pushkal | 2025-10-02 | Sell | 541 | $450.81 | $243.9K | Direct |
| Garg Pushkal | 2025-10-02 | Sell | 332 | $451.86 | $150.0K | Direct |
| Garg Pushkal | 2025-10-02 | Sell | 668 | $452.69 | $302.4K | Direct |
| Garg Pushkal | 2025-10-02 | Sell | 244 | $454.84 | $111.0K | Direct |
| Garg Pushkal | 2025-10-02 | Sell | 73 | $455.82 | $33.3K | Direct |
| Garg Pushkal | 2025-10-02 | Sell | 147 | $457.43 | $67.2K | Direct |
| Garg Pushkal | 2025-10-02 | Sell | 3 | $457.64 | $1.4K | Direct |
| Garg Pushkal | 2025-10-02 | Sell | 329 | $453.77 | $149.3K | Direct |
| Garg Pushkal | 2025-10-02 | Sell | 115 | $446.53 | $51.4K | Direct |
| Garg Pushkal | 2025-10-02 | Sell | 56 | $447.92 | $25.1K | Direct |
| Garg Pushkal | 2025-10-02 | Sell | 180 | $448.77 | $80.8K | Direct |
| Garg Pushkal | 2025-10-02 | Sell | 249 | $449.79 | $112.0K | Direct |
| Garg Pushkal | 2025-10-01 | Buy | 3.1K | $0.00 | $0.00 | Direct |
| Garg Pushkal | 2025-10-01 | Buy | 2.9K | $0.00 | $0.00 | Direct |
| Net change | 0 | −$2.7M | ||||
About Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc. is a pioneering biotechnology company dedicated to transforming the lives of patients through RNA interference (RNAi) therapeutics. This scientific approach allows for innovative treatments that can silence genes responsible for certain diseases, offering a unique angle on genetic therapies. Alnylam's primary focus is on developing therapeutics for genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases, contributing to redefining how these conditions are treated. The company's groundbreaking work in RNAi provides a platform for addressing otherwise untreatable or poorly managed medical conditions, positioning it as a leader in the biotechnology sector. With numerous collaborations, partnerships, and a growing pipeline of therapeutics, Alnylam plays a crucial role in advancing modern medicine and contributing to the evolving landscape of genetic therapeutics. Headquartered in Cambridge, Massachusetts, Alnylam underscores the critical intersection of innovation, medicine, and gene science in the financial and pharmaceutical markets.
Track ALNY insider activity
Get alerted when Alnylam Pharmaceuticals Inc. executives buy or sell their shares.